GLA’s Scientific Advisory Board (SAB) provides strategic guidance and direction for our research and scientific programs. It is made up of some of the most distinguished researchers and clinical innovators in multidisciplinary fields in Lyme and tick-borne disease. These leaders advise on overall strategy to direct GLA’s grant funds into research programs judged to have the best prospects of delivering measurable results and the greatest impact.

GLA hosts an annual symposium for SAB members and grant recipients, to foster brainstorming of new diagnostic and therapeutic measures, communication of ideas and collaboration.

The Financial Review Sub-Committee of the SAB is composed of business leaders with extensive strategic, operational and senior management experience. Its priority is to bridge the gap between the research community and the marketplace with the goal of transitioning successful research programs into accessible treatments that are readily available to patients.

Committee Members

  • Armin Alaedini Armin Alaedini  Ph.D.
  • John Belisle John Belisle  Ph.D.
  • catherine brissette Catherine A. Brissette  Ph.D.
  • Charles Chiu  M.D., Ph.D.
  • Allison DeLong  M.S.
  • Richard Goldstein  DVM
  • linden hu Linden Hu  M.D.
  • Andreas Kogelnik  M.D.
  • Richard T. Marconi  Ph.D.
  • adriana marques Adriana Marques  M.D.
  • Scott J. Mellis  M.D., Ph.D.
  • Richard S. Ostfeld  Ph.D.
  • Utpal Pal  Ph.D.
  • Mark J. Soloski  Ph.D.
  • susan swedo Susan Swedo  M.D.
  • mark wooten R. Mark Wooten  Ph.D.

GLA: Research Leadership

  • timothy sellati Timothy J. Sellati, Ph.D.  Chief Scientific Officer
  • mayla hsu Mayla Hsu, Ph.D.  Director of Research and Science

Financial Review Committee

  • robert kobre Robert Kobre  CPA, MBA
  • scott santarella Scott Santarella  CEO
  • Brian Scanlan